TY - JOUR
T1 - Nano-navigated macrophages
T2 - Piercing liver inflammation, fibrosis, and cancer
AU - Moreno-Lanceta, Alazne
AU - Edelman, Elazer R.
AU - Conde, João
AU - Melgar-Lesmes, Pedro
N1 - Funding Information:
This work was supported by grants to P.M-L. from Ministerio de Ciencia, Innovaci\u00F3n y Universidades (grants PID2021-123426OB-I00/funded by MCIU/ AEI /10.13039/501100011033, \u201CERDF A way of making Europe,\u201D and CNS2022-135148/funded by MCIU/ AEI /10.13039/501100011033 and by the European Union Next Generation EU/PRTR). P.M-L. was additionally supported by the Ramon y Cajal Program (RYC2018-0Z23971-I/MCIN/ AEI /10.13039/501100011033) and FSE invierte en tu futuro. A.M.-L. had a Formaci\u00F3n de Personal Investigador (FPI) grant from Ministerio de Ciencia, Innovaci\u00F3n y Universidades and FSE invierte en tu futuro (reference: PRE2019-088097). A.M.-L. was additionally supported by a grant from the Spanish Association for the Study of the Liver ( AEEH ): \u201CBeca para el Aprendizaje de Nuevas Tecnolog\u00EDas 2023.\u201D E.R.E. was supported by a grant (R01 GM 49039) from the National Institutes of Health. The Centro de Investigaci\u00F3n Biom\u00E9dica en Red de Enfermedades Hep\u00E1ticas y Digestivas (CIBERehd) is funded by the Instituto de Salud Carlos III . This work was also supported by RedFibro (RED2022-134485-T) - 2022 call for \u00ABRESEARCH NETWORKS\u00BB, within the framework of the Programa Estatal del Plan Estatal de Investigaci\u00F3n Cient\u00EDfica, T\u00E9cnica y de Innovaci\u00F3n 2021\u20132023, and the Consolidated Research Group of the Generalitat de Catalunya AGAUR (2021 SGR 00881). J.C. acknowledges the European Research Council \u2013 ( ERC ) Starting Grant 848325, Brussels, Belgium, for financial support.
Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/10/2
Y1 - 2024/10/2
N2 - The incidence of chronic liver disease is increasing worldwide. Inflammation is a driving force in this disease; however, there is a need to further define the centrality of macrophages. With advances in nanotechnology, the therapeutic landscape of modulating macrophages against liver inflammation, fibrosis, and cancer can be considered using nanotherapeutics.
AB - The incidence of chronic liver disease is increasing worldwide. Inflammation is a driving force in this disease; however, there is a need to further define the centrality of macrophages. With advances in nanotechnology, the therapeutic landscape of modulating macrophages against liver inflammation, fibrosis, and cancer can be considered using nanotherapeutics.
UR - http://www.scopus.com/inward/record.url?scp=85207712769&partnerID=8YFLogxK
U2 - 10.1016/j.matt.2024.09.003
DO - 10.1016/j.matt.2024.09.003
M3 - Comment/debate
AN - SCOPUS:85207712769
SN - 2590-2393
VL - 7
SP - 3234
EP - 3237
JO - Matter
JF - Matter
IS - 10
ER -